Compare IDEXX Laboratories, Inc. (IDXX) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares Russell 2000 ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares Russell 2000 ETF trades at $278.93 (market cap $77.70B). The key difference: iShares Russell 2000 ETF is the larger of the two by market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares Russell 2000 ETF for 83 Days on average.
| IDXX | IWM | |
|---|---|---|
Market Cap | $40.43B | $77.70B |
Volume | 692,164 | 35,598,983 |
Sector | Health | — |
52-Week High | $766.68 | $305.06 |
52-Week Low | $504.70 | $229.13 |
Typical Hold Time | 46 Days | 83 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
IWM trades at $277.63, showing minimal daily movement with a slight decline of 0.03%. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, while oscillators remain neutral. The ETF faces headwinds from Federal Reserve rate hike concerns and underperformance relative to large-cap indices. Recent institutional selling and negative media coverage highlight ongoing challenges for small-cap exposure.
The outlook remains cautious as small-caps face pressure from tightening financial conditions and energy price volatility. While offering diversification from tech-heavy indices, IWM's inclusion of unprofitable companies and decade-long underperformance versus the S&P 500 present significant hurdles for near-term outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
